Management of the pregnant patient by the rheumatologist

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Rheumatic disorders are more common in women. Thus, clinicians may be faced with the challenge of managing a rheumatic disease during pregnancy. The physiological and immunological changes that occur in pregnancy can impact disease symptoms and activity. An integrated team approach that relies on input from the rheumatologist, maternal-fetal medicine specialist, and the patient, is the best insurance for a good outcome. Treatment regimens must be modified as not all medications are compatible with pregnancy. In general, nonsteroidal anti-inflammatory drugs up to the third trimester, glucocorticoids, antimalarials, sulfasalazine, and the immunosuppressive agents azathioprine and cyclosporine A may be used during pregnancy while methotrexate, leflunomide, cyclophosphomide, and the biologics should be avoided. Copyright Remedica Medical Education and Publishing.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalInternational Journal of Advances in Rheumatology
Volume9
Issue number4
StatePublished - Dec 1 2011

Fingerprint

Pregnancy
leflunomide
Sulfasalazine
Azathioprine
Antimalarials
Third Pregnancy Trimester
Immunosuppressive Agents
Rheumatic Diseases
Insurance
Biological Products
Methotrexate
Cyclosporine
Glucocorticoids
Anti-Inflammatory Agents
Mothers
Medicine
Rheumatologists
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Management of the pregnant patient by the rheumatologist. / Bermas, Bonnie L.

In: International Journal of Advances in Rheumatology, Vol. 9, No. 4, 01.12.2011, p. 115-122.

Research output: Contribution to journalReview article

@article{435d96cb90e740e99bfb76cfdb98bf75,
title = "Management of the pregnant patient by the rheumatologist",
abstract = "Rheumatic disorders are more common in women. Thus, clinicians may be faced with the challenge of managing a rheumatic disease during pregnancy. The physiological and immunological changes that occur in pregnancy can impact disease symptoms and activity. An integrated team approach that relies on input from the rheumatologist, maternal-fetal medicine specialist, and the patient, is the best insurance for a good outcome. Treatment regimens must be modified as not all medications are compatible with pregnancy. In general, nonsteroidal anti-inflammatory drugs up to the third trimester, glucocorticoids, antimalarials, sulfasalazine, and the immunosuppressive agents azathioprine and cyclosporine A may be used during pregnancy while methotrexate, leflunomide, cyclophosphomide, and the biologics should be avoided. Copyright Remedica Medical Education and Publishing.",
author = "Bermas, {Bonnie L.}",
year = "2011",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "115--122",
journal = "International Journal of Advances in Rheumatology",
issn = "1478-856X",
publisher = "Remedica Medical Education and Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Management of the pregnant patient by the rheumatologist

AU - Bermas, Bonnie L.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Rheumatic disorders are more common in women. Thus, clinicians may be faced with the challenge of managing a rheumatic disease during pregnancy. The physiological and immunological changes that occur in pregnancy can impact disease symptoms and activity. An integrated team approach that relies on input from the rheumatologist, maternal-fetal medicine specialist, and the patient, is the best insurance for a good outcome. Treatment regimens must be modified as not all medications are compatible with pregnancy. In general, nonsteroidal anti-inflammatory drugs up to the third trimester, glucocorticoids, antimalarials, sulfasalazine, and the immunosuppressive agents azathioprine and cyclosporine A may be used during pregnancy while methotrexate, leflunomide, cyclophosphomide, and the biologics should be avoided. Copyright Remedica Medical Education and Publishing.

AB - Rheumatic disorders are more common in women. Thus, clinicians may be faced with the challenge of managing a rheumatic disease during pregnancy. The physiological and immunological changes that occur in pregnancy can impact disease symptoms and activity. An integrated team approach that relies on input from the rheumatologist, maternal-fetal medicine specialist, and the patient, is the best insurance for a good outcome. Treatment regimens must be modified as not all medications are compatible with pregnancy. In general, nonsteroidal anti-inflammatory drugs up to the third trimester, glucocorticoids, antimalarials, sulfasalazine, and the immunosuppressive agents azathioprine and cyclosporine A may be used during pregnancy while methotrexate, leflunomide, cyclophosphomide, and the biologics should be avoided. Copyright Remedica Medical Education and Publishing.

UR - http://www.scopus.com/inward/record.url?scp=84863944969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863944969&partnerID=8YFLogxK

M3 - Review article

VL - 9

SP - 115

EP - 122

JO - International Journal of Advances in Rheumatology

JF - International Journal of Advances in Rheumatology

SN - 1478-856X

IS - 4

ER -